NETs 101

Friday, December 21, 2018, 12:00 AM - Wednesday, December 21, 2022, 12:00 AM PST, Online Course

Internet Enduring Material Sponsored by the Stanford University School of Medicine. Presented by the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Over the past several decades, the incidence of neuroendocrine tumors (NETs) has sharply increased.  The selection of initial and subsequent therapies requires careful consideration of both tumor and treatment characteristics. This online CME course seeks to update physicians concerning guidelines and best practice recommendations, so they understand the basics of NET nomenclature, pathology, epidemiology, and identify appropriate treatment strategies.

Intended Audience

This course is designed to meet the educational needs of physicians in oncology, radiology, endocrinology, hematology, medical oncology, surgical oncology, nuclear radiology.

Release Date: December 21, 2018

Latest Review Date: December 21, 2019

Expiration Date: December 21, 2022

Estimated Time to Complete: 0.5 hours

CME Credits Offered: 0.50

Registration Fee: FREE

Disclosures:
The following planner and speaker has indicated that they have relationships with industry to disclose relative to the content of this activity:

Pamela L. Kunz, MD
Assistant Professor of Medicine - Oncology
Stanford University Medical Center
Course Director/ Speaker
Advisory Board: Lexicon, Novartis, Advanced Accelerator Applications 
Contracted Research: Advanced Accelerator Applications, Genentech Incyte, Ipsen, Lexicon Pharmaceuticals Merck, Xencor

The following  planner and reviewer has indicated that that they have no relationships with industry to disclose relative to the content of this activity:

Tyler Johnson, MD
Clinical Assistant Professor of Medicine - Oncology
Stanford University School of Medicine
Reviewer, Planner

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours)

1. Review the basics of NET nomenclature, pathology, and epidemiology and identify appropriate treatment options.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency

The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws. You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

Bibliography

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-712.

Dasari A, Shen C, Halperin D, et al. Changing Trends in the Incidence, Prevalence and Survival of Neuroendocrine Tumors in the United States: A SEER Population-Based Study of 64, 971 Cases. JAMA Oncology. 2017.

Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855-1863.

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018 Jan;59(1):66-74.

More bibliographic information can be found in the Resources and References section of the course

This activity is supported in part by educational grants from Advanced Accelerator Applications USA, Inc., Ipsen Biopharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation.